Inhalatory suchego proszku w dobie pandemii COVID-19 – co jest ważne dla pacjenta? Praca przeglądowa
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
kwi 26, 2021
Słowa kluczowe:
inhalatory suchego proszku, inhalator Forspiro®, COVID-19, astma, POChP, glikokortykosteroidy wziewne, długo działający β2-mimetyk, terapia SMART
##plugins.themes.bootstrap3.article.main##
Abstrakt
W artykule przedstawiono możliwości terapii inhalacyjnej astmy za pomocą inhalatorów suchego proszku w dobie pandemii COVID-19. Zwrócono uwagę na inhalatory suchego proszku obecne na polskim rynku zawierające kombinację glikokortykosteroidów wziewnych z długo działającym β2-mimetykiem. Pokazano podobieństwa i różnice między różnymi DPI, akcentując cechy, które są ważne z punktu widzenia pacjenta. Szczegółowo omówiono inhalator Forspiro®, który ma unikalne mechanizmy kontroli używania i poprawności techniki inhalacji, ważne dla chorego w dobie pandemii COVID-19 i teleporad medycznych.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
Emeryk , A., Emeryk-Maksymiuk , J., Janeczek , K., & Grzywna , K. (2021). Inhalatory suchego proszku w dobie pandemii COVID-19 – co jest ważne dla pacjenta? . Alergoprofil, 17(2), 3-9. https://doi.org/10.24292/01.AP.172210421
Numer
Dział
THERAPY
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Tran K, Cimon K, Severn M et al. Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: A systematic review. PLoS ONE. 2012; 7(4): e35797.
2. Shaker MS, Oppenheimer J, Grayson M et al. COVID-19: pandemic contingency planning for the allergy and immunology clinic. J Allergy Clin Immunol Pract. 2020; 8(5): 1477-88.
3. Kowalski ML, Bartuzi Z, Bręborowicz A et al. Stanowisko grupy ekspertów Polskiego Towarzystwa Alergologicznego w sprawie postępowania u chorych na astmę i choroby alergiczne w okresie pandemii SARS-CoV-2. Alergologia Polska – Polish Journal of Allergology. 2020; 7(2): 1-7.
4. McGrath JA, O’Sullivan A, Bennett G et al. Investigation of the quantity of exhaled aerosols released into the environment during nebulization. Pharmaceutics. 2019; 11(2): 75.
5. Ari A. Practical strategies for a safe and effective delivery of aerosolized medications to patients with COVID-19 Respir Med. 2020; 167: 105987. http://doi.org/10.1016/j.rmed.2020.105987.
6. Emeryk A, Pirożyński M, Mazurek H et al. Polski przewodnik inhalacyjny. 2nd ed. Via Medica, Gdańsk 2021: 1-48.
7. Pirożyński M. Terapia wziewna ze szczególnym uwzględnieniem steroidów w okresie pandemii COVID-19. Alergia. 2020; 1: 4-6.
8. Emeryk A, Pirożyński M, Mazurek H et al. Stanowisko polskich ekspertów dotyczące nebulizacji w okresie pandemii COVID-19. Terapia. 2020; 28: 12-8.
9. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA). Update 2020. https://ginasthma.org/wp-content/uploads/2020/06/GINA-2020-mainreport-June-2020-wms.pdf (access: 30.12.2020).
10. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease 2020 Report. https://goldcopd.org/wp-content/uploads/2019/11/GOLD- 2020-REPORT-ver1.0wms.pdf (access: 30.12.2020).
11. Haidl P, Heindl S, Siemon K et al. Inhalation device requirements for patients inhalation maneuvers. Respir Med. 2016; 118: 65-75.
12. Emeryk A, Pirożyński M. Nowe inhalatory suchego proszku. Pneumonol Alergol Pol. 2015; 83: 83-7.
13. Grant AC, Walker R, Hamilton M et al. The ELLIPTA® dry powder inhaler: design, functionality, in vitro dosing performance and critical task compliance by patients and caregivers. J Aerosol Med Pulm Drug Deliv. 2015; 28(6): 474-85.
14. Canonica GW, Arp J, Keegstra JR et al. Spiromax, a new dry powder inhaler: dose consistency under simulated real- world conditions. J Aerosol Med Pulm Drug Deliv. 2015; 28: 309-19.
15. Emeryk A, Pirożyński M. Forspiro – nowy inhalator suchego proszku. Czy zbliżamy się do ideału? Pneumonol Alergol Pol. 2016; 84(6): 64-9.
16. Lavorini F, Janson Ch, Braido F et al. What to consider before prescribing inhaled medications: a pragmatic approach for evaluating the current inhaler landscape. Ther Adv Respir Dis. 2019; 13: 1753466619884532.
17. Lung deposition and particle size of Fluticasone Furoate/ vilanterol. Data on file. GKS 2014N188664_00.2014.
18. Chapman KR, Fogarty CM, Peckitt C et al. Delivery characteristics and patients’ handling of two single-dose dry powder inhalers used in COPD. Int J Chron Obstruct Pulmon Dis. 2011; 6: 353-63.
19. Hoppentocht M, Hagedoorn P, Frijlink HW et al. Technological and practical challenges of dry powder inhalers and formulations. Adv Drud Deliv Rev. 2014; 75: 18-31.
20. Johal B, Howald M, Fischer M et al. Fine particle profile of fluticasone propionate/formoterol fumarate versus other combination products: the DIFFUSE Study. Comb Prod Ther. 2013; 3: 39-51.
21. Demoly P, Hagedoorn P, de Boer AH et al. The clinical relevance of dry powder inhaler performance for drug delivery. Respir Med. 2014; 108(8): 1195-203.
22. de Boer AH, Gjaltema D, Hagedoorn P et al. Can extrafine dry powder aerosols improve lung deposition? Eur J Pharm Biopharm. 2015; 96: 143-51.
23. Turpeinen A, Eriksson P, Happonen A et al Consistent dosing through the salmeterol-fluticasone propionate Easyhaler for the management of asthma and chronic obstructive pulmonary disease: robustness analysis across the Easyhaler lifetime. J Aerosol Med Pulm Drug Deliv. 2020. http://doi.org/10.1089/jamp.2020.1592.
24. Jõgi R, Lähelmä S, Vahteristo M et al. In vitro flow rate dependency of delivered dose and fine particle dose of salmeterol/ fluticasone propionate Easyhaler and Seretide Diskus with patient flow rates collected in a randomized controlled trial. J Aerosol Med Pulm Drug Deliv. 2019; 32(2): 88-98.
25. Panigone S, Sandri F, Ferri R et al. Environmental impact of inhalers for respiratory diseases: decreasing the carbon footprint while preserving patient-tailored treatment. BMJ Open Resp Res. 2020; 7: e000571.
26. Product Carbon Footprint: Life Cycle Assessment Report for Orion Corporation, Orion Pharma. A study of 4 varieties of Easyhalers. Carbon Footprint Ltd 2020. https://www.orion.fi/en/Sustainability/stories-about-responsibility/inhaler-environmental-footprint/ (access: 25.12.2020).
27. https://www.propellerhealth.com/press/press-release/propeller-health-sensor-to-be-co-packaged-with-recently-approved-enerzair-breezhaler-asthma-medication-in-europe/ (access: 10.12.2020).
28. Wilkinson AJK, Braggins R, Steinbach I et al. Costs of switching to low global warming potential inhalers. An economic and carbon footprint analysis of NHS prescription data in England. BMJ Open. 2019; 9: e028763.
29. Janson Ch, Henderson R, Löfdahl M et al. Carbon footprint impact of the choice of inhalers for asthma and COPD. Thorax. 2020; 75(1): 82-4.
30. www.greeninhaler.org/inhaler-comparison/ (access: 30.12.2020).
31. Reece C, Swanbury PH. An Overview of the design verification testing process for the GyroHaler® dry powder inhaler. https://aerosol-soc.com/abstracts/overview-design-verification-testing-process-gyrohaler-dry-powder-inhaler/ (access: 23.03.2021).
32. Tarsin WY, Pearson SB, Assi KH et al. Emitted dose estimates from Seretide Diskus and Symbicort Turbuhaler following inhalation by severe asthmatics. Int J Pharm. 2006; 316(1-2): 131-7.
33. Voshaar T, Spinola M, Linnane P et al. Comparing usability of NEXThaler with other inhaled corticosteroid/long-acting β2-agonist fixed combination dry powder inhalers in asthma patients. J Aerosol Med Pulm Drug Deliv. 2014; 27(5): 363-70.
34. Hill LS. A comparison of the performance of two modern multidose dry powder asthma inhalers. Respir Med. 1998; 92: 105-10.
35. Kondo T, Tanigaki T, Yokoyama H et al. Impact of holding position during inhalation on drug release from a reservoir-, blister- and capsule-type dry powder inhaler. J Asthma. 2017; 54(8): 792-7.
36. http://leki.urpl.gov.pl/files/49_Airbufo_Forspiro.pdf (access: 21.12.2020).
37. Sanchis J, Gich I, Pedersen S; on behalf of Aerosol Drug Management Improvement Team (ADMIT). Systematic review of errors in inhaler use: has patient technique improved over time? Chest. 2016; 150: 394-406.
38. Chrystyn H, van der Palen J, Sharma R et al. Device errors in asthma and COPD: systematic literature review and meta- analysis. NPJ Prim Care Respir Med. 2017; 27: 22.
39. Luczak-Wozniak K, Dabrowska M, Domagala I et al. Mishandling of pMDI and DPI inhalers in asthma and COPD – Repetitive and non-repetitive errors. Pulm Pharmacol Ther. 2018; 51: 65-72.
40. Lavorini F, Usmani OS. Correct inhalation technique is critical in achieving good asthma control. Prim Care Respir J. 2013; 22: 385-6.
41. Usmani OS, Lavorini F, Marshall J et al. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. Respir Res. 2018; 19: 10.
42. Lewis A, Torvinen S, Dekhuijzen PNR et al. The economic burden of asthma and chronic obstructive pulmonary disease and the impact of poor inhalation technique with commonly prescribed dry powder inhalers in three European countries. BMC Health Serv Res. 2016; 16: 251-63.
43. Price D, Bosnic-Anticevich S, Briggs A et al. Inhaler competence in asthma: common errors, barriers to use and recommended solutions. Respir Med. 2013; 107: 37-46.
44. Emeryk A, Pirożyński M, Emeryk-Maksymiuk J. Dry powder inhalers - between the doctor and the patient. Adv Respir Med. 2018; 86(suppl I): 28-41.
45. Virchow JC, Akdis CA, Darba J et al. A review of the value of innovation in inhalers for COPD and asthma. J Mark Access Health Policy. 2015; 3: 1-8.
46. https://citywire.co.uk/funds-insider/news/ace-vectura-leaps-on-inhaler-development/a261150 (access: 15.03.2021).
47. Jones S, Gath I, Weuthen T. Comparison of inspiratory flow rates using an innovative dry powder inhaler (DPI) in patients with mild-severe asthma and severe COPD. Eur Respir J. 2014; 44: P941.
48. Jones S, Weuthen T, Harmer QJ et al. P7 Assessing the intuitive ease of use a novel dry powder inhaler, the Forspiro device, for asthma and COPD. Thorax. 2012; 67: A66-A7.
49. Jones S, Clarke R, Eason S et al. Comparison of an innovative multi-dose inhaler with the attributes of an ‘ideal’ inhaler: A multicentre, randomised controlled trial (RCT). Eur Respir J. 2014; 44: P937.
50. Virchow JC, Weuthen T, Harmer QJ et al. Identifying the features of an easy-to-use and intuitive dry powder inhaler for asthma and chronic obstructive pulmonary disease therapy: results from a 28-day device handling study, and an airflow resistance study. Expert Opin Drug Deliv. 2014; 11(12): 1849-57.
51. Backer V, Leif Bjermer L, Refvem OK et al. A multicenter, open-label, noninterventional study to evaluate the impact on clinical effects, userfriendliness and patients’ acceptance of AirFluSal Forspiro in the treatment of asthma under real-life conditions (ASSURE). Pragm Observ Res. 2019; 10: 29-39.
2. Shaker MS, Oppenheimer J, Grayson M et al. COVID-19: pandemic contingency planning for the allergy and immunology clinic. J Allergy Clin Immunol Pract. 2020; 8(5): 1477-88.
3. Kowalski ML, Bartuzi Z, Bręborowicz A et al. Stanowisko grupy ekspertów Polskiego Towarzystwa Alergologicznego w sprawie postępowania u chorych na astmę i choroby alergiczne w okresie pandemii SARS-CoV-2. Alergologia Polska – Polish Journal of Allergology. 2020; 7(2): 1-7.
4. McGrath JA, O’Sullivan A, Bennett G et al. Investigation of the quantity of exhaled aerosols released into the environment during nebulization. Pharmaceutics. 2019; 11(2): 75.
5. Ari A. Practical strategies for a safe and effective delivery of aerosolized medications to patients with COVID-19 Respir Med. 2020; 167: 105987. http://doi.org/10.1016/j.rmed.2020.105987.
6. Emeryk A, Pirożyński M, Mazurek H et al. Polski przewodnik inhalacyjny. 2nd ed. Via Medica, Gdańsk 2021: 1-48.
7. Pirożyński M. Terapia wziewna ze szczególnym uwzględnieniem steroidów w okresie pandemii COVID-19. Alergia. 2020; 1: 4-6.
8. Emeryk A, Pirożyński M, Mazurek H et al. Stanowisko polskich ekspertów dotyczące nebulizacji w okresie pandemii COVID-19. Terapia. 2020; 28: 12-8.
9. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA). Update 2020. https://ginasthma.org/wp-content/uploads/2020/06/GINA-2020-mainreport-June-2020-wms.pdf (access: 30.12.2020).
10. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease 2020 Report. https://goldcopd.org/wp-content/uploads/2019/11/GOLD- 2020-REPORT-ver1.0wms.pdf (access: 30.12.2020).
11. Haidl P, Heindl S, Siemon K et al. Inhalation device requirements for patients inhalation maneuvers. Respir Med. 2016; 118: 65-75.
12. Emeryk A, Pirożyński M. Nowe inhalatory suchego proszku. Pneumonol Alergol Pol. 2015; 83: 83-7.
13. Grant AC, Walker R, Hamilton M et al. The ELLIPTA® dry powder inhaler: design, functionality, in vitro dosing performance and critical task compliance by patients and caregivers. J Aerosol Med Pulm Drug Deliv. 2015; 28(6): 474-85.
14. Canonica GW, Arp J, Keegstra JR et al. Spiromax, a new dry powder inhaler: dose consistency under simulated real- world conditions. J Aerosol Med Pulm Drug Deliv. 2015; 28: 309-19.
15. Emeryk A, Pirożyński M. Forspiro – nowy inhalator suchego proszku. Czy zbliżamy się do ideału? Pneumonol Alergol Pol. 2016; 84(6): 64-9.
16. Lavorini F, Janson Ch, Braido F et al. What to consider before prescribing inhaled medications: a pragmatic approach for evaluating the current inhaler landscape. Ther Adv Respir Dis. 2019; 13: 1753466619884532.
17. Lung deposition and particle size of Fluticasone Furoate/ vilanterol. Data on file. GKS 2014N188664_00.2014.
18. Chapman KR, Fogarty CM, Peckitt C et al. Delivery characteristics and patients’ handling of two single-dose dry powder inhalers used in COPD. Int J Chron Obstruct Pulmon Dis. 2011; 6: 353-63.
19. Hoppentocht M, Hagedoorn P, Frijlink HW et al. Technological and practical challenges of dry powder inhalers and formulations. Adv Drud Deliv Rev. 2014; 75: 18-31.
20. Johal B, Howald M, Fischer M et al. Fine particle profile of fluticasone propionate/formoterol fumarate versus other combination products: the DIFFUSE Study. Comb Prod Ther. 2013; 3: 39-51.
21. Demoly P, Hagedoorn P, de Boer AH et al. The clinical relevance of dry powder inhaler performance for drug delivery. Respir Med. 2014; 108(8): 1195-203.
22. de Boer AH, Gjaltema D, Hagedoorn P et al. Can extrafine dry powder aerosols improve lung deposition? Eur J Pharm Biopharm. 2015; 96: 143-51.
23. Turpeinen A, Eriksson P, Happonen A et al Consistent dosing through the salmeterol-fluticasone propionate Easyhaler for the management of asthma and chronic obstructive pulmonary disease: robustness analysis across the Easyhaler lifetime. J Aerosol Med Pulm Drug Deliv. 2020. http://doi.org/10.1089/jamp.2020.1592.
24. Jõgi R, Lähelmä S, Vahteristo M et al. In vitro flow rate dependency of delivered dose and fine particle dose of salmeterol/ fluticasone propionate Easyhaler and Seretide Diskus with patient flow rates collected in a randomized controlled trial. J Aerosol Med Pulm Drug Deliv. 2019; 32(2): 88-98.
25. Panigone S, Sandri F, Ferri R et al. Environmental impact of inhalers for respiratory diseases: decreasing the carbon footprint while preserving patient-tailored treatment. BMJ Open Resp Res. 2020; 7: e000571.
26. Product Carbon Footprint: Life Cycle Assessment Report for Orion Corporation, Orion Pharma. A study of 4 varieties of Easyhalers. Carbon Footprint Ltd 2020. https://www.orion.fi/en/Sustainability/stories-about-responsibility/inhaler-environmental-footprint/ (access: 25.12.2020).
27. https://www.propellerhealth.com/press/press-release/propeller-health-sensor-to-be-co-packaged-with-recently-approved-enerzair-breezhaler-asthma-medication-in-europe/ (access: 10.12.2020).
28. Wilkinson AJK, Braggins R, Steinbach I et al. Costs of switching to low global warming potential inhalers. An economic and carbon footprint analysis of NHS prescription data in England. BMJ Open. 2019; 9: e028763.
29. Janson Ch, Henderson R, Löfdahl M et al. Carbon footprint impact of the choice of inhalers for asthma and COPD. Thorax. 2020; 75(1): 82-4.
30. www.greeninhaler.org/inhaler-comparison/ (access: 30.12.2020).
31. Reece C, Swanbury PH. An Overview of the design verification testing process for the GyroHaler® dry powder inhaler. https://aerosol-soc.com/abstracts/overview-design-verification-testing-process-gyrohaler-dry-powder-inhaler/ (access: 23.03.2021).
32. Tarsin WY, Pearson SB, Assi KH et al. Emitted dose estimates from Seretide Diskus and Symbicort Turbuhaler following inhalation by severe asthmatics. Int J Pharm. 2006; 316(1-2): 131-7.
33. Voshaar T, Spinola M, Linnane P et al. Comparing usability of NEXThaler with other inhaled corticosteroid/long-acting β2-agonist fixed combination dry powder inhalers in asthma patients. J Aerosol Med Pulm Drug Deliv. 2014; 27(5): 363-70.
34. Hill LS. A comparison of the performance of two modern multidose dry powder asthma inhalers. Respir Med. 1998; 92: 105-10.
35. Kondo T, Tanigaki T, Yokoyama H et al. Impact of holding position during inhalation on drug release from a reservoir-, blister- and capsule-type dry powder inhaler. J Asthma. 2017; 54(8): 792-7.
36. http://leki.urpl.gov.pl/files/49_Airbufo_Forspiro.pdf (access: 21.12.2020).
37. Sanchis J, Gich I, Pedersen S; on behalf of Aerosol Drug Management Improvement Team (ADMIT). Systematic review of errors in inhaler use: has patient technique improved over time? Chest. 2016; 150: 394-406.
38. Chrystyn H, van der Palen J, Sharma R et al. Device errors in asthma and COPD: systematic literature review and meta- analysis. NPJ Prim Care Respir Med. 2017; 27: 22.
39. Luczak-Wozniak K, Dabrowska M, Domagala I et al. Mishandling of pMDI and DPI inhalers in asthma and COPD – Repetitive and non-repetitive errors. Pulm Pharmacol Ther. 2018; 51: 65-72.
40. Lavorini F, Usmani OS. Correct inhalation technique is critical in achieving good asthma control. Prim Care Respir J. 2013; 22: 385-6.
41. Usmani OS, Lavorini F, Marshall J et al. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. Respir Res. 2018; 19: 10.
42. Lewis A, Torvinen S, Dekhuijzen PNR et al. The economic burden of asthma and chronic obstructive pulmonary disease and the impact of poor inhalation technique with commonly prescribed dry powder inhalers in three European countries. BMC Health Serv Res. 2016; 16: 251-63.
43. Price D, Bosnic-Anticevich S, Briggs A et al. Inhaler competence in asthma: common errors, barriers to use and recommended solutions. Respir Med. 2013; 107: 37-46.
44. Emeryk A, Pirożyński M, Emeryk-Maksymiuk J. Dry powder inhalers - between the doctor and the patient. Adv Respir Med. 2018; 86(suppl I): 28-41.
45. Virchow JC, Akdis CA, Darba J et al. A review of the value of innovation in inhalers for COPD and asthma. J Mark Access Health Policy. 2015; 3: 1-8.
46. https://citywire.co.uk/funds-insider/news/ace-vectura-leaps-on-inhaler-development/a261150 (access: 15.03.2021).
47. Jones S, Gath I, Weuthen T. Comparison of inspiratory flow rates using an innovative dry powder inhaler (DPI) in patients with mild-severe asthma and severe COPD. Eur Respir J. 2014; 44: P941.
48. Jones S, Weuthen T, Harmer QJ et al. P7 Assessing the intuitive ease of use a novel dry powder inhaler, the Forspiro device, for asthma and COPD. Thorax. 2012; 67: A66-A7.
49. Jones S, Clarke R, Eason S et al. Comparison of an innovative multi-dose inhaler with the attributes of an ‘ideal’ inhaler: A multicentre, randomised controlled trial (RCT). Eur Respir J. 2014; 44: P937.
50. Virchow JC, Weuthen T, Harmer QJ et al. Identifying the features of an easy-to-use and intuitive dry powder inhaler for asthma and chronic obstructive pulmonary disease therapy: results from a 28-day device handling study, and an airflow resistance study. Expert Opin Drug Deliv. 2014; 11(12): 1849-57.
51. Backer V, Leif Bjermer L, Refvem OK et al. A multicenter, open-label, noninterventional study to evaluate the impact on clinical effects, userfriendliness and patients’ acceptance of AirFluSal Forspiro in the treatment of asthma under real-life conditions (ASSURE). Pragm Observ Res. 2019; 10: 29-39.